Use of AI helping fight wildfires by predicting where they might start
The Kiskatinaw River wildfire along the B.C.-Alberta border can be seen from the sky in early June. (Photo: Alberta Wildfire)
Wildfire season has become a common occurrence over the last few years with large-scale fires destroying large swaths of cities – and uprooting lives.
To combat this, scientists are developing new technology using artificial intelligence (AI) to predict where fires will take place beforehand so that they can be prevented.
The rising number of wildfires that have become a part of spring and summer in Alberta over the past decade is pushing several Canadian companies to develop ways to prevent the kinds seen in Fort McMurray in 2016 and in Jasper National Park last year.
Some use drone mapping, others such as AI6 use complicated computer systems.
Millions of simulations measure minute data such as temperature, rain levels, wind patterns and dryness.
Gio Roberti of AI6 says software sifts through the results, creating a map that predicts the likeliest spots where a wildfire could start and spread.
'We are able to capture to understand what the probability of a fire occurring today is and in 10, 20, 50 years, according to different climate change scenarios,' Roberti told CTV News Edmonton.
'There might be cases where mitigation measures might be taken where, for example, preventive burns or fuel thinning and things like that.'
The technology is new, but Roberti says it's already in use, identifying potential hot spots to municipalities and insurance companies.
'People take preventative measures when they see their community on the map,' he said.
Roberti said the technology could also work beyond the Canadian border.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
36 minutes ago
- Globe and Mail
2 No-Brainer Artificial Intelligence Stocks to Buy Right Now
No matter where you are on the artificial intelligence (AI) debate -- for or against -- there's no denying that it's transforming the way people work. Companies of all shapes and sizes are integrating into their daily workflows, and new industries are popping up because of it. The mass adoption of AI could result in a market size of more than $15 trillion by 2030, according to PwC research. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Fortunately, there are tons of AI companies out there that actually have a foothold in the market and aren't just flash-in-the-pan opportunities. Here are two well-established companies that are already benefiting from this trend and could be great AI stocks for years to come. 1. Taiwan Semiconductor Taiwan Semiconductor Manufacturing (NYSE: TSM) does exactly what its name describes -- it manufactures processors for companies. The world's leading chip designers, including Nvidia, rely on Taiwan Semiconductor (often referred to as TSMC) to make their processors because the company is so good at it. TSMC manufactures an estimated 90% of the world's artificial intelligence semiconductors, making it the clear leader in this market. This dominance led to TSMC's revenue rising 41% in the first quarter of 2025 to $25.5 billion and diluted earnings per share jumping 60% to $2.12 per American depository receipt (ADR). TSMC relies on its technological lead in semiconductor manufacturing to stay ahead of its competitors, and so far, it's still leading the pack. The company is focused on its 5-nanometer (nm) and 3nm chip production and management said recently that there continues to be "strong demand" for both. The company's CEO, C.C. Wei, said early this year he expects TSMC's artificial intelligence revenue to double this year compared to last year and recently reiterated that forecast. Taiwan Semiconductor stock has already gained 142% over the past three years, so what makes the stock a buy right now? Demand for semiconductors hasn't slowed down yet, and no one knows when or if it will. Companies are locked in an AI race right now, and a big part of that involves getting their hands on the most advanced AI chips. With TSMC's dominance in semiconducting manufacturing and it already holding a lead in advanced AI processors, the company is poised to benefit from chip demand as long as tech giants need the best processors available. And despite its share price gains, TSMC stock has a price to earnings ratio of just 25, which is below the P/E multiple of the broader S&P 500. 2. Microsoft Microsoft (NASDAQ: MSFT) has made itself an important player in artificial intelligence by making strategic investments in ChatGPT creator OpenAI over the past several years. The early move gave Microsoft access to one of the most advanced AI chatbots on the market, and it quickly implemented ChatGPT into everything from its Microsoft 365 suite of productivity tools to its GitHub Copilot coding assistant. That's helped Microsoft stay relevant in a rapidly shifting tech market and benefit from AI's growth. Part of Microsoft's AI strategy has been to offer more advanced services with its Azure cloud computing platform, which has helped result in a 35% jump in cloud services sales in the fiscal third quarter (which ended March 31). Microsoft is the second-largest public cloud computing provider with 21% market share, trailing only Amazon, which holds 30%. Microsoft has narrowed this gap over the past few years, and its investments in artificial intelligence infrastructure could make it an even stronger contender. The company will spend $80 billion on cloud infrastructure this fiscal year alone to stay ahead of the competition. Microsoft's stock is a bit more expensive than Taiwan Semiconductor's, with a P/E multiple of 36. But with Microsoft already off to a strong start in implementing advanced AI into its software and benefiting from AI cloud services, the company is setting itself up to remain a leading tech player for years to come. Should you invest $1,000 in Taiwan Semiconductor Manufacturing right now? Before you buy stock in Taiwan Semiconductor Manufacturing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Taiwan Semiconductor Manufacturing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Microsoft, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
National Post
an hour ago
- National Post
Music streamer Spotify tells CRTC not to regulate it like radio
OTTAWA — Music streamer Spotify says Canada's federal broadcast regulator shouldn't impose rules meant for radio on streaming services. Article content Appearing before a CRTC hearing Friday, company representatives compared regulating Spotify like a radio station to treating Uber like a horse and buggy operation. Article content 'To apply yesterday's tools to today's platforms risks dulling Canada's success on the global music stage,' said Xenia Manning, Spotify's director of global music policy. Article content 'It is essential to assess whether a real problem exists that justifies regulatory intervention. In our view, the evidence is clear. There is no market failure in audio streaming that would warrant intervention by the CRTC.' Article content Article content Spotify said the Broadcasting Act doesn't give the CRTC the authority to 'regulate the terms of trade between online undertakings, including good faith negotiations and commercial disputes.' Article content It said the CRTC's proposals 'would see it imposing dispute resolution and commercial negotiation requirements on online undertakings that are plainly outside the scope of broadcasting.' Article content The CRTC is holding a hearing on market dynamics as part of its work to implement the Online Streaming Act, which updated broadcasting laws to capture online platforms. Article content Article content During the hearing, large telecom and broadcasting companies like Bell and Rogers called on the CRTC to loosen existing rules for traditional players. Article content Article content They took aim at regulations governing how cable channels must be packaged and disputes about carriage of cable channels. Article content Bell, which appeared Wednesday, asked the CRTC to get rid of the rule the regulator implemented nearly a decade ago requiring companies to offer a $25 basic cable package. Article content Colette Watson, president of Rogers' media division, said less than half of Canadian households now subscribe to cable, satellite or IPTV service. Article content
Globe and Mail
2 hours ago
- Globe and Mail
Islet cell transplant trial outcome ‘major milestone' toward cure for diabetes
When Amanda Smith learned at the age of 25 that she had late-onset Type 1 diabetes, she considered the diagnosis a death sentence. The nurse, from London, Ont., had a particularly dim view of the disease because she grew up watching her mother struggle with it. Her mother would slur her words and lose consciousness when her blood sugar bottomed out. Once, Ms. Smith's grandfather had to break a window to reach her mother, who was passed out in her home holding a banana she had tried to consume to raise her blood sugar. 'It literally eats you from the inside out,' said Ms. Smith, now 36. 'It rots your teeth, it destroys your body, your vision. The complications that come with Type 1 diabetes are so extreme.' Ms. Smith is confident now that those complications won't be in her future. In February of 2023, she became the first Canadian to receive a transplant of islet cells – the cells in the pancreas that make insulin – derived from embryonic stem cells. The transplant freed her from insulin and gave her blood sugar control akin to a non-diabetic. It was performed at Toronto General Hospital, the institution where insulin was first tested more than 100 years ago. On Friday, the results of the clinical trial in which Ms. Smith participated were published in the New England Journal of Medicine. The early-phase trial was small, and the procedure has a significant downside in that patients must take anti-rejection drugs for life, just like recipients of organ transplants. For people living with diabetes, the push for medical coverage isn't political, it's personal Nonetheless, the study's outcome counts as 'spectacular,' according to James Shapiro, who holds the Canada Research Chair in transplant surgery and regenerative medicine at the University of Alberta and was not involved in the study. Ten of the 12 participants who received a full dose of the cells were insulin-independent one year later. 'This is a major advance and a major milestone along the journey towards a cure,' he said. Dr. Shapiro was himself responsible for an earlier breakthrough on that path. In 2000, he and his colleagues at the University of Alberta published a seminal paper on a method they developed for safely and effectively transplanting islet cells from deceased donors into patients with Type 1 diabetes. They dubbed their regimen the 'Edmonton Protocol.' 'We used to call it the drive-through transplant,' Dr. Shapiro said, because giving patients islet cells was less risky and burdensome than a whole pancreas transplant. The cells are infused into patients under mild sedation with an IV-drip into the portal vein of the liver. The breakthrough described in the new paper is that the islet cells transplanted into Ms. Smith were derived not from deceased donors but from embryonic stem cells, which function as a type of source code that scientists can coax into becoming any cell in the human body. The supply of such lab-created islets could, in theory, be limitless, unlike the supply of deceased donor islets. Semaglutide, or Ozempic, reduces symptoms of feared diabetes' complication, study finds Trevor Reichman, director of the pancreas and islet transplant program at the University Health Network's Ajmera Transplant Centre, said the most encouraging result is that the islet-cell transplants eliminated dangerous blood sugar 'lows' that can cause confusion, seizures and unconsciousness. He ran the study site at UHN and is an author of the new paper. 'All of them, essentially, were able to get rid of their hypoglycemic episodes,' Dr. Reichman said, 'so all of the real risks to them, all of the lows, were essentially eliminated.' Still, the international trial, funded by Boston-based Vertex Pharmaceuticals, wasn't without its challenges. The company paused it temporarily last year after two participants died, though not from taking Zimislecel, the brand name of the new islet therapy. Vertex expects to apply for regulatory approval of Zimislecel starting next year. One participant died of severe dementia 30 months after the infusion. That patient had pre-existing neurocognitive impairment and, before joining the trial, had suffered a brain injury during a motor-vehicle accident caused by a severe blood sugar low. The other died of cryptococcal meningitis, a fungal infection caused by a sinus surgery. The death was related to the immunosuppressant medication that the participant was taking to preserve the islet transplant, the study said. That death underscores the tradeoff that people with Type 1 diabetes would have to make with Zimislecel, said Rémi Rabasa-Lhoret, director of the Metabolic Diseases Research Unit and The Diabetes Clinic at the Montreal Clinical Research Institute. He wonders how many people with Type 1 would be willing to take anti-rejection drugs for life, especially now that advances such as insulin pumps have made diabetes easier to manage for some patients. 'It's probably going to be a very narrow population,' Dr. Rabasa-Lhoret said. The next step for scientists is finding a way to genetically engineer or encapsulate islets so the immune system won't view them as hostile invaders. In the meantime, Ms. Smith said taking three pills, three times a day to suppress her immune system is a breeze compared with the round-the-clock work of keeping her blood sugar in check. Her 10-year-old daughter, Draya, used to say she wanted to become a doctor to cure diabetes. Now, she talks of being a pilot or engineer. 'I would do this a million times over compared to the maintenance I used to have to do to keep myself alive,' Ms. Smith said.
